Table 1.

Summary recommendations and funding for study vaccines^2,29,30

	Publicly funded vaccine for adults
Study vaccine	New Brunswick	Nova Scotia	Recommendations by NACI for routine adult immunization
Hepatitis A	No	No	• Travellers to hepatitis A–endemic areas Individuals at increased risk of infection, especially people with medical, occupational or lifestyle risks
Hepatitis B	No	No	• Travellers to hepatitis B–endemic areas Individuals at increased risk of infection, especially people with medical, occupational or lifestyle risks
High-dose TIV	No	No (except long-term care facility residents)	Adults 65 years of age and older31
HZ	No	No	Adults 50 years of age and older without contraindications3
MenACWY	No	No	• Adults up to and including 24 years of age not immunized in adolescence • High-risk individuals including those with occupational risk for exposure and underlying medical conditions • Close contact with a case of IMD caused by MenACWY Travellers to areas where meningococcal vaccine is recommended or required
MenB	No	No	• Individuals at high risk of meningococcal disease caused by MenB, including those with occupational risk for exposure and underlying medical conditions • Close contact with a case of IMD caused by MenB • Risk during IMD outbreaks caused by MenB No contraindications to the vaccine and wish to be immunized32
Tdap	Yes	Yes	• One dose in adulthood One dose in every pregnancy, ideally between 27 and 32 weeks of gestation
Typhoid fever	No	No	• People travelling to endemic areas Occupational risk of exposure

HZ, herpes zoster; IMD, invasive meningococcal disease; MenACWY, quadrivalent conjugate meningococcal vaccine; MenB, meningococcal B vaccine; NACI, National Advisory Committee on Immunization; Tdap, tetanus-diphtheria-acellular pertussis vaccine; TIV, trivalent inactivated influenza vaccine.